Effects of co-medicated drugs on cyclophosphamide bioactivation in human liver microsomes

Anti-Cancer Drugs

Volumn 16, Issue 3, 2005, Pages 331-336

  De Jonge, Milly E ^a   Huitema, Alwin D R ^a   Van Dam, Selma M ^a   Rodenhuis, Sjoerd ^b   Beijnen, Jos H ^a,b  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Cyclophosphamide; Drug drug interactions; Inhibition; Metabolism

Indexed keywords

4 HYDROXYCYCLOPHOSPHAMIDE; ACICLOVIR; AMPHOTERICIN B; CARBOPLATIN; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450; DEXAMETHASONE; FLUCONAZOLE; GRANISETRON; ITRACONAZOLE; LORAZEPAM; MESNA; METOCLOPRAMIDE; ONDANSETRON; RANITIDINE; ROXITHROMYCIN; TEMAZEPAM; THIOTEPA;

ARTICLE; CHEMOTHERAPY; CONTROLLED STUDY; DRUG ACTIVATION; DRUG ACTIVITY; DRUG EFFECT; DRUG INHIBITION; DRUG MEGADOSE; DRUG METABOLISM; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; LIVER MICROSOME; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; CELLS, CULTURED; CYCLOPHOSPHAMIDE; DRUG INTERACTIONS; HUMANS; MICROSOMES, LIVER;

EID: 14144254437     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200503000-00013     Document Type: Article

References (38)

1. Chang TKH, Weber GF, Crespi CL, Waxman DJ. Differential activation of cyclophosphamide and ifosfamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 1993; 53:5629-5637.
2. m catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics 1997; 7:211-221.
3. Roy P, Yu LJ, Crespi CL, Waxman DJ. Development of a substrate activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Disp 1999; 27:655-666.
4. Chang TKH, Yu L, Maurel P, Waxman DJ. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res 1997; 57:1946-1954.
5. Ren S, Yang JS, Kalhorn TF, Slattery JT. Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes. Cancer Res 1997; 57:4229-4235.
6. Yu L, Waxman DJ. Role of cytochrome P450 in oxazaphosphorine metabolism. Deactivation via N-dechloroethylation and activation via 4-hydroxylation catalyzed by distinct subsets of rat liver cytochromes P450. Drug Metab Disp 1996; 24:1254-1262.
7. Moore MJ. Clinical Pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 1991; 20:194-208.
8. Bohnenstengel F, Hofmann U, Eichelbaum M, Kroemer HK. Characterization of the cytochrome P450 involved in side-chain oxidation of cyclophosphamide in humans. Eur J Clin Pharmacol 1996; 51:297-301.
9. Moreb J, Schweder M, Suresh A, Zucali JR. Over-expression of the human aldehyde dehydrogenase class I results in increased resistance to 4-hydroperoxycyclophosphamide. Cancer Gene Ther 1996; 3:24-30.
10. Yule SM, Boddy AV, Cole M, Price L, Wyllie R, Tasso MJ, et al. Cyclophosphamide pharmacokinetics in children. Br J Clin Pharmacol 1996; 41:13-119.
11. Bagley CM, Bostick FW, DeVita VT. Clinical pharmacology of cyclophosphamide. Cancer Res 1973; 33:226-233.
12. Hassan M, Ljungman P, Ringdén O, Hassan Z, Oberg G, Nilsson C, et al. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity. Bone Marrow Transplant 2000; 25:915-924.
13. Faber OK, Mouridsen HT, Skovsted L. The effect of chloramphenicol and sulphaphenazole on the biotransformation of cyclophosphamide in man. Br J Clin Pharmacol 1975; 2:281-285.
14. Carlens S, Ringden O, Aschan J, Hagglund H, Ljungman P, Mattsson J, et al. Risk factors in bone marrow transplant recipients with leukaemia. Increased relapse risk in patients treated with ciprofloxacin for gut decontamination. Clin Transplant 1998; 12:84-92.
15. Yule SM, Walker D, Cole M, McSorley L, Cholerton S, Daly AK, et al. The effect of fluconazole on cyclophosphamide metabolism in children. Drug Metab Disp 1999; 27:417-421.
16. Marr KA, Leisenring W, Crippa F, Slattery JT, Corey L, Boeckh M, et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood 2004; 103:1557-1559.
17. Chen TL, Passoscoelho JL, Noe DA, Kennedy MJ, Black KC, Colvin OM, et al. Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast-cancer receiving high-dose chemotherapy followed by autologous bone-marrow transplantation. Cancer Res 1995; 55:810-816.
18. Anderson LW, Chen T, Colvin OM, Grochow LB, Collins JM, Kennedy MJ, et al. Cyclophosphamide and 4-hydroxycyclophsophamide/ aldophosphamide kinetics in patients receiving high-dose cyclophosphamide chemotherapy. Clin Cancer Res 1996; 2:1481-1487.
19. Huitema ADR, Kerbusch T, Tibben MM, Rodenhuis S, Beijnen JH. Reduction of cyclophosphamide-bioactivation by thiotepa: critical sequence-dependency in high-dose chemotherapy regimens. Cancer Chemother Pharmacol 2000; 46:119-127.
20. Rae JM, Soukhova NV, Flockhart DA, Desta Z. Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6:implications for cyclophosphamide metabolism. Drug Metab Disp 2002; 30:525-530.
21. Lindley C, Hamilton G, McCune JS, Faucette S, Shord SS, Hawke RL. The effect of cyclophosphamide with and without dexamethasone on cytochrome P450 3A4 and 2B6 in human hepatocytes. Drug Metab Disp 2002; 30:814-821.
22. Busse D, Busch FW, Bohnenstengel F, Eichelbaum M, Fischer P, Opalinska J, et al. Dose escalation of cyclophosphamide in patients with breast cancer: consequences for pharmacokinetics and metabolism. J Clin Oncol 1997; 15:1885-1896.
23. Gilbert CJ, Petros WP, Vredenburgh J, Hussein A, Ross M, Rubin P, et al. Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer. Cancer Chemother Pharmacol 1998; 42:497-503.
24. Cagnoni PJ, Matthes S, Day TC, Bearman SI, Shpall EJ, Jones RB. Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics. Bone Marrow Transplant 1999; 24:1-4.
25. Jao JY, Jusko WJ, Cohen JL. Phenobarbital effects on cyclophosphamide pharmacokinetics in man. Cancer Res 1972; 32:2761-2764.
26. Cohen JL, Jao JY, Jusko WJ. Pharmacokinetics of cyclophosphamide in man. Br J Pharmacol 1971; 43:677-80.
27. Sladek NE, Priest J, Doeden D, Mirocha CJ, Pathre S, Krivit W. Plasma half-life and urinary excretion of cyclophosphamide in children. Cancer Treat Rep 1980; 64:1061-1066.
28. Sladek NE, Doeden D, Powers JF, Krivit W. Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation. Cancer Treat Rep 1984; 68:1247-1254.
29. Williams ML, Wainer IW, Embree L, Barnett M, Granvil CL, Ducharme MP. Enantioselectlve induction of cyclophosphamide metabolism by phenytoin. Chirality 1999; 11:569-574.
30. Slattery JT, Kalhorn TF, McDonald GB, Lambert K, Buckner CD, Bensinger WI, et al. Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients. J Clin Oncol 1996; 14:1484-1494.
31. De Jonge ME, Huitema ADR, Van Dam SM, Beijnen JH, Rodenhuis S. Significant induction of cyclophosphamide and thiotepa metabolism by phenytoin. Cancer Chemother Pharmacol 2004; in press.
32. Faber OK, Mouridsen HT, Skovsted L. The biotransformation of cyclophosphamide in man: influence of prednisone. Acta Pharmacol Toxicol 1974; 35:195-200.
33. Boddy AV, Furtun Y, Sardas S, Sardas O, Idle JR. Individual variation in the activation and inactivation of metabolic pathways of cyclophosphamide. J Natl Cancer Inst 1992; 84:1744-1748.
34. Huitema ADR, Spaander M, Mathôt RAA, Tibben MM, Holtkamp MJ, Beijnen JH, et al. Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thioTEPA and carboplatin. Ann Oncol 2002; 13:374-384.
35. De Jonge ME, Van Dam SM, Hillebrand MJX, Rosing H, Huitema AD, Rodenhuis S, et al. Simultaneous quantification of cyclophosphamide, 4- hydroxycyclophosphamide, N,N′N′-triethylenethiophosphoramide (thiotepa) and N′,N′N′-triethylenephosphoramide (tepa) in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry (LC-MS/MS). J Mass Spectrom 2004; 39:262-271.
36. Low JE, Borch RF, Sladek NE. Further studies on the conversion of 4-hydroxyoxaphosphorines to reactive mustards and acrolein in inorganic buffers. Cancer Res 1983; 43:5815-5820.
37. Albengres E, Le Louet H, Tillement JP. Systemic antifungal agents. Drug interactions of clinical significance. Drug Safety 1998; 18:83-97.
38. Xie HJ, Broberg U, Griskevicius L, Lundgren S, Carlens S, Meurling L, et al. Alteration of pharmacokinetics of cyclophosphamide and suppression of the cytochrome P450 genes by ciprofloxacin. Bone Marrow Transplant 2003; 31:197-203.